# Antibodies against Human Cytomegalovirus in the Pathogenesis of Systemic Sclerosis: A Gene Array Approach

**Authors:** Claudio Lunardi, Marzia Dolcino, Dimitri Peterlana, Caterina Bason, Riccardo Navone, Nicola Tamassia, Ruggero Beri, Roberto Corrocher, Antonio Puccetti

PMC · DOI: 10.1371/journal.pmed.0030002 · 2005-12-06

## TL;DR

This study explores how antibodies against a human cytomegalovirus protein may contribute to the development of systemic sclerosis by affecting endothelial cells and fibroblasts.

## Contribution

The study demonstrates a novel link between anti-cytomegalovirus antibodies and fibroblast activation in systemic sclerosis.

## Key findings

- Anti-UL94 antibodies induce endothelial cell apoptosis and upregulate genes related to adhesion, chemokines, and apoptosis.
- Dermal fibroblasts exposed to anti-UL94 antibodies show a 'scleroderma-like' phenotype with increased extracellular matrix and cytokine gene expression.
- Results were confirmed using real-time PCR, ELISA, and Western blotting.

## Abstract

Systemic sclerosis is an autoimmune disease characterized by immunological abnormalities, vascular damage, and fibroblast proliferation. We have previously shown that a molecular mimicry mechanism links antibodies against the human-cytomegalovirus-derived protein UL94 to the pathogenesis of systemic sclerosis. The UL94 epitope shows homology with NAG-2, a surface molecule highly expressed on endothelial cells. Anti-UL94 peptide antibodies purified from patients' sera induce apoptosis of endothelial cells upon engagement of the NAG-2–integrin complex.

We show here that NAG-2 is expressed on dermal fibroblasts and that anti-UL94 antibodies bind to fibroblasts. We have used the gene array strategy (Affimetrix oligonucleotide microarrays) to analyze the transcriptional profile in response to a 4-h and an 8-h treatment with antibodies against the UL94 peptide in endothelial cells and dermal fibroblasts. Exposure of endothelial cells to anti-UL94 antibodies had a profound impact on gene expression, resulting in the upregulation of 1,645 transcripts. Several gene clusters were upregulated including genes encoding adhesion molecules, chemokines, colony-stimulating factors (CSFs), growth factors, and molecules involved in apoptosis. Following antibody stimulation, dermal fibroblasts showed an upregulation of 989 transcripts and acquired a “scleroderma-like” phenotype. Indeed, genes involved in extracellular matrix deposition, growth factors, chemokines, and cytokines were upregulated. We confirmed the microarray results by real-time quantitative polymerase chain reaction and by measuring some of the corresponding proteins with ELISA and Western blotting.

Our results show that anti-human-cytomegalovirus antibodies may be linked to the pathogenesis of systemic sclerosis not only by inducing endothelial cell activation and apoptosis but also by causing activation of fibroblasts, one of the hallmarks of the disease.

Anti-human-cytomegalovirus antibodies may be linked to the pathogenesis of systemic sclerosis by inducing endothelial cell activation and apoptosis, and fibroblast activation and proliferation.

## Linked entities

- **Genes:** TSPAN4 (tetraspanin 4) [NCBI Gene 7106]
- **Proteins:** UL94 (tegument protein UL16), TSPAN4 (tetraspanin 4), scb (scab)
- **Diseases:** systemic sclerosis (MONDO:0005100)

## Full-text entities

- **Genes:** CASP1 (caspase 1) [NCBI Gene 834] {aka ICE, IL1BC, P45}, ICAM1 (intercellular adhesion molecule 1) [NCBI Gene 3383] {aka BB2, CD54, P3.58}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, EMILIN1 (elastin microfibril interfacer 1) [NCBI Gene 11117] {aka ATBFS, EMI, EMILIN, HMN10, HMND10, gp115}, ELN (elastin) [NCBI Gene 2006] {aka ADCL1, SVAS, WBS, WS}, TNC (tenascin C) [NCBI Gene 3371] {aka 150-225, DFNA56, GMEM, GP, HXB, JI}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, TSPAN4 (tetraspanin 4) [NCBI Gene 7106] {aka NAG-2, NAG2, TETRASPAN, TM4SF7, TSPAN-4}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, NOS3 (nitric oxide synthase 3) [NCBI Gene 4846] {aka EC-NOS, ECNOS, MYMY8, NOSIII, cNOS, eNOS}, FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, TNFRSF25 (TNF receptor superfamily member 25) [NCBI Gene 8718] {aka APO-3, DDR3, DR3, LARD, TNFRSF12, TR3}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, IER3 (immediate early response 3) [NCBI Gene 8870] {aka DIF-2, DIF2, GLY96, IEX-1, IEX-1L, IEX1}, COMP (cartilage oligomeric matrix protein) [NCBI Gene 1311] {aka CTS2, EDM1, EPD1, MED, PSACH, THBS5}, MMP1 (matrix metallopeptidase 1) [NCBI Gene 4312] {aka CLG}, IL11 (interleukin 11) [NCBI Gene 3589] {aka AGIF, IL-11}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, DPT (dermatopontin) [NCBI Gene 1805] {aka TRAMP}, CX3CL1 (C-X3-C motif chemokine ligand 1) [NCBI Gene 6376] {aka ABCD-3, C3Xkine, CXC3, CXC3C, NTN, NTT}, PIM1 (Pim-1 proto-oncogene, serine/threonine kinase) [NCBI Gene 5292] {aka PIM}, MMP3 (matrix metallopeptidase 3) [NCBI Gene 4314] {aka CHDS6, MMP-3, SL-1, STMY, STMY1, STR1}, TGFBR3 (transforming growth factor beta receptor 3) [NCBI Gene 7049] {aka BGCAN, betaglycan}, BMP1 (bone morphogenetic protein 1) [NCBI Gene 649] {aka OI13, PCOLC, PCP, TLD}, DAPK1 (death associated protein kinase 1) [NCBI Gene 1612] {aka DAPK, ROCO3}, CCN2 (cellular communication network factor 2) [NCBI Gene 1490] {aka CTGF, HCS24, IBP-8, IGFBP8, KMD, NOV2}, EFNA1 (ephrin A1) [NCBI Gene 1942] {aka B61, ECKLG, EPLG1, GMAN, LERK-1, LERK1}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, UL94 [NCBI Gene 3077496], NDUFA13 (NADH:ubiquinone oxidoreductase subunit A13) [NCBI Gene 51079] {aka B16.6, CDA016, CGI-39, GRIM-19, GRIM19, MC1DN28}, JUNB (JunB proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3726] {aka AP-1}, CSRP2 (cysteine and glycine rich protein 2) [NCBI Gene 1466] {aka CRP2, LMO5, SmLIM}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, SELP (selectin P) [NCBI Gene 6403] {aka CD62, CD62P, GMP140, GRMP, LECAM3, PADGEM}, SMAD1 (SMAD family member 1) [NCBI Gene 4086] {aka BSP-1, BSP1, JV4-1, JV41, MADH1, MADR1}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, F3 (coagulation factor III, tissue factor) [NCBI Gene 2152] {aka CD142, TF, TFA}, CXCL10 (C-X-C motif chemokine ligand 10) [NCBI Gene 3627] {aka C7, IFI10, INP10, IP-10, SCYB10, crg-2}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, BGN (biglycan) [NCBI Gene 633] {aka DSPG1, MRLS, PG-S1, PGI, SEMDX, SLRR1A}, CCL7 (C-C motif chemokine ligand 7) [NCBI Gene 6354] {aka FIC, MARC, MCP-3, MCP3, NC28, SCYA6}, EDN1 (endothelin 1) [NCBI Gene 1906] {aka ARCND3, ET1, HDLCQ7, PPET1, QME}, MMP10 (matrix metallopeptidase 10) [NCBI Gene 4319] {aka SL-2, STMY2}, CXCL12 (C-X-C motif chemokine ligand 12) [NCBI Gene 6387] {aka IRH, PBSF, SCYB12, SDF1, TLSF, TPAR1}, CCL3 (C-C motif chemokine ligand 3) [NCBI Gene 6348] {aka G0S19-1, LD78, LD78ALPHA, MIP-1-alpha, MIP1A, SCI}, PDGFA (platelet derived growth factor subunit A) [NCBI Gene 5154] {aka PDGF-A, PDGF1}, SELE (selectin E) [NCBI Gene 6401] {aka CD62E, ELAM, ELAM1, ESEL, LECAM2, selectin-e}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, VWF (von Willebrand factor) [NCBI Gene 7450] {aka F8VWF, VWD}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CXCL1 (C-X-C motif chemokine ligand 1) [NCBI Gene 2919] {aka FSP, GRO1, GROa, MGSA, MGSA-a, NAP-3}, AKT2 (AKT serine/threonine kinase 2) [NCBI Gene 208] {aka HIHGHH, PKBB, PKBBETA, PRKBB, RAC-BETA}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, SMAD3 (SMAD family member 3) [NCBI Gene 4088] {aka HSPC193, HsT17436, JV15-2, LDS1C, LDS3, MADH3}, AGTR1 (angiotensin II receptor type 1) [NCBI Gene 185] {aka AG2S, AGTR1B, AT1, AT1AR, AT1B, AT1BR}, VCAM1 (vascular cell adhesion molecule 1) [NCBI Gene 7412] {aka CD106, INCAM-100}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, IGF2 (insulin like growth factor 2) [NCBI Gene 3481] {aka C11orf43, GRDF, IGF-II, PP9974, SRS3}, TAGLN (transgelin) [NCBI Gene 6876] {aka SM22, SM22-alpha, SMCC, TAGLN1, TGLN, WS3-10}
- **Diseases:** hypoxia (MESH:D000860), infection (MESH:D007239), autoimmune disease (MESH:D001327), fibrotic diseases (MESH:D004194), graft-versus-host disease (MESH:D006086), endothelial dysfunction (MESH:D014652), lung damage (MESH:D008171), SSc (MESH:D012595), inflammation (MESH:D007249), cardiovascular disease (MESH:D002318), hypoxic (MESH:D002534), structural and (MESH:D020914), SSc skin lesions (MESH:D012871), immunologic abnormalities (MESH:D007154), pulmonary fibrosis (MESH:D011658), capillary damage (OMIM:163000), involvement (MESH:C564676), fibrosis (MESH:D005355), Diffuse SSc (MESH:D045743), rheumatoid arthritis (MESH:D001172), vascular damage (MESH:D057772), digital ischemia (MESH:D007511)
- **Chemicals:** sepharose (MESH:D012685), glycine (MESH:D005998), glutaraldehyde (MESH:D005976), nitric oxide (MESH:D009569), magnesium chloride (MESH:D015636), SYBR Green (MESH:C098022), prostacyclin (MESH:D011464), SDS (MESH:D012967), NP-40 (MESH:C010615), PBS (MESH:D007854), sodium chloride (MESH:D012965), GGAGIWLLP (-), TRIzol (MESH:C411644),  (MESH:D018925),  (MESH:D036341),  (MESH:D015815)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Human betaherpesvirus 5 (no rank) [taxon 10359], Cytomegalovirus (genus) [taxon 10358], Homo sapiens (human, species) [taxon 9606]

## Figures

11 figures with captions in the complete paper: https://tomesphere.com/paper/PMC1298939/full.md

---
Source: https://tomesphere.com/paper/PMC1298939